Reducing Frailty for Older Cancer Survivors Using Supplements II
This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
Frailty|Inflammation
DRUG: Epigallocatechin-3-Gallate (EGCG)|DRUG: Microcrystalline cellulose (MCC)|DIETARY_SUPPLEMENT: Ascorbic Acid (Vitamin C)
Change of physical frailty measured using the Short Physical Performance Battery (SPPB) in patients in the EGCG arm compared to placebo; change in SPPB scores from baseline to 12 weeks., We will assess the change in SPPB scores from baseline to 12 weeks after baseline in patients in the EGCG intervention arm compared to the placebo arm., 12 Weeks
This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.